High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience-Reference-Cited by-同舟云学术

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience

Published:2022-06 Issue:6 Volume:3 Page:100328
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Piper-Vallillo A.J.,Rotow Julia K.,Aredo Jacqueline V.,Shaverdashvili Khvaramze,Luo Jia,Carlisle Jennifer W.,Husain Hatim,Muzikansky Alona,Heist Rebecca S.,Rangachari Deepa,Ramalingam Suresh S.,Wakelee Heather A.,Yu Helena A.,Sequist Lecia V.,Bauml Joshua M.,Neal Joel W.,Piotrowska Zofia

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2019

2. Pre-clinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity;YJWYZ;Clin Cancer Res,2016

3. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

4. CNS response to osimertinib versus Standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non–small-cell lung cancer;Reungwetwattana;J Clin Oncol,2018

5. Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status;Yu;Medicine,2019

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimus-Era Dose Finding for Rare Cancers;Cancer Discovery;2024-06-03

2. Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases;Scientific Reports;2024-06-03

3. High-dose short-term osimertinib treatment is effective in patient-derived metastatic colorectal cancer organoids;BJC Reports;2024-04-03

4. Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib;JTO Clinical and Research Reports;2024-03

5. Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis;Lung Cancer;2024-02